Clinical Trial Update: Panobinostat Maintenance After HSCT fo High-risk AML and MDS [Phase 3]

View source ↗

Summary

Phase 3 trial update on panobinostat maintenance after stem cell transplant in high-risk AML and MDS was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• Panobinostat (Panobinostat)

Snippet

Sponsor: Goethe University | Conditions: Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS) | Phase 3 | Status: TERMINATED